Chronic Myeloid Leukemia

Common Name(s)

Chronic Myeloid Leukemia

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Chronic Myeloid Leukemia" returned 1536 free, full-text research articles on human participants. First 3 results:

Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
 

Author(s): Yu-Fen Tsai, Wen-Chuan Huang, Shih-Feng Cho, Hui-Hua Hsiao, Yi-Chang Liu, Sheng-Fung Lin, Ta-Chih Liu, Chao-Sung Chang

Journal: Medicine (Baltimore). 2018 Jun;97(26):e11322.

 

Nonadherence is common in patients with chronic myeloid leukemia (CML) and leads to treatment failure and poor outcomes. Side effects due to treatment are also common in patients with CML. However, no study has investigated the link between side effects and medication adherence for ...

Last Updated: 31 Dec 1969

Go To URL
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
 

Author(s): Dong-Wook Kim, Susanne Saussele, Loretta A Williams, Hesham Mohamed, Yuanxin Rong, Teresa Zyczynski, Javier Pinilla-Ibarz, Elisabetta Abruzzese

Journal: Ann. Hematol.. 2018 Aug;97(8):1357-1367.

 

Chronic, low-grade adverse events are common in patients with chronic myeloid leukemia who are treated with imatinib. These events may decrease patient quality of life and adherence, and may ultimately contribute to a suboptimal response. Alternative, second-generation tyrosine kinase ...

Last Updated: 31 Dec 1969

Go To URL
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
 

Author(s): David M Ross, Tamas Masszi, María Teresa Gómez Casares, Andrzej Hellmann, Jesper Stentoft, Eibhlin Conneally, Valentin Garcia-Gutierrez, Norbert Gattermann, Philipp D le Coutre, Bruno Martino, Susanne Saussele, Francis J Giles, Jerald P Radich, Giuseppe Saglio, Weiping Deng, Nancy Krunic, Véronique Bédoucha, Prashanth Gopalakrishna, Andreas Hochhaus

Journal: J. Cancer Res. Clin. Oncol.. 2018 May;144(5):945-954.

 

ENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis.

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Chronic Myeloid Leukemia" returned 180 free, full-text review articles on human participants. First 3 results:

Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.
 

Author(s): Martin C Müller, Francisco Cervantes, Henrik Hjorth-Hansen, Jeroen J W M Janssen, Dragana Milojkovic, Delphine Rea, Gianantonio Rosti

Journal: Crit. Rev. Oncol. Hematol.. 2017 Dec;120():52-59.

 

Five tyrosine kinase inhibitors (TKIs) are currently approved in the European Union for treatment of chronic myeloid leukemia (CML) and all have considerable overlap in their indications. While disease-specific factors such as CML phase, mutational status, and line of treatment are ...

Last Updated: 31 Dec 1969

Go To URL
Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.
 

Author(s): Fabian Lang, Lydia Wunderle, Heike Pfeifer, Susanne Schnittger, Gesine Bug, Oliver G Ottmann

Journal:

 

BACKGROUND CML presenting with a variant Philadelphia translocation, atypical BCR-ABL transcript, additional chromosomal aberrations, and evolving MDS is uncommon and therapeutically challenging. The prognostic significance of these genetic findings is uncertain, even as singular ...

Last Updated: 31 Dec 1969

Go To URL
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.
 

Author(s): Nazanin Aghel, Diego Hernan Delgado, Jeffrey Howard Lipton

Journal:

 

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML). Despite their significant impact on the management of CML, there is growing evidence that TKIs may cause cardiovascular and/or metabolic complications. In this review, ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 20 Feb 2018

Go to URL
Regional Central Database Recording of Chronic Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 17 Nov 2017

Go to URL
Bosutinib in Elderly Chronic Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 31 Aug 2017

Go to URL